LOBBYIST

Ted Lehman

174ACTIVITIES

9ORGS REPRESENTED

7BILLS

Revolving door — covered positions

Federal positions Ted held before / during the 2-year LDA window. This is the credibility signal — who they were inside the building before they started lobbying it.

Chief of Staff, Senator Tillis

Senate Judiciary Committee-Counsel, then Chief Counsel for Nominations and Senior Counsel

Senate Judiciary Committee-Staff Assistant and Legislative Assistant

Organizations represented

Orgs whose LD-2 filings list Ted as an active lobbyist, sorted by activity volume.

Todd Strategy Group76 activities American Medical Association28 activities Pharmaceutical Research and Manufacturers of America (PhRMA)22 activities Bristol Myers Squibb12 activities Eli Lilly and Company12 activities U.s. Chamber of Commerce Global Innovation Policy Center9 activities NCTA - The Internet & Television Association6 activities Pfizer6 activities U.S. Chamber of Commerce3 activities

Bills they file on

S. 86415 mentions

H.R. 16728 mentions

H.R. 9468 mentions

H.R. 52694 mentions

S. 10402 mentions

S. 10412 mentions

H.R. 22142 mentions

Topics in Filings

Policy topics Ted files on across all their LD-2 activities.

Medicare and Medicaid Issues×18

HELP Copays Act×15

Physician Payment Reform×14

Intellectual property protection×12

Prescription Drug Pricing Policy×12

Part D changes×11

Prescription drug payment reform. 340B issues×11

General Medicare and Medicaid Issues×11

Drug Pricing and Access×11

Pharmaceutical Supply Chain×11

Pharmacy Benefit Managers×11

Show all 60 topics (+48 more) ▾

Medicare/Medicaid payment reform×10

Supply Chain Issues×10

Alzheimer's Disease×10

Maintaining Investments in New Innovation Act×8

ORPHAN Cures Act×8

General telecommunications issues×6

Biosimilars reimbursement issues×6

Pharmacy Benefit Manager Reform×6

Anti Obesity Medication×6

Medicare/Medicaid Coverage and Reimbursement×6

PDUFA. 340B Program×6

Prescription drug pricing, including MDRP×4

Substance Use Disorder Policy×4

Medicaid drug rebate program×4

General Education on Apollo Global Management×4

Insurance regulation×4

Prescription drug pricing×4

Prostate cancer screening×4

Women's health×4

340B Program×4

Home Infusion for Part B Products×4

Medicare Reimbursement for New Technologies×4

Pediatric Priority Review Voucher Program×4

General issues×4

Diagnostics for patients with rare disease×4

Multi-Cancer Early Detection×4

Drug pricing×4

Medicare reimbursement for diagnostics×4

Medicare Contractor Reform×4

Lab test regulatory and reimbursement reform×4

Medicare Reimbursement for Prescription Drugs×4

Screening and Diagnosis×4

PET scan coverage and reimbursement and dementia care. 340B Program×4

PPRV×4

Medicare coverage of molecular testing for solid organ allograft rejection×4

Medicare payment of clinical laboratory tests×4

Prior authorization of molecular tests×4

Oncology/Artificial Intelligence×4

Hepatitis C Funding×4

Drug pricing and Medicare, including implementation×2

Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients×2

Drug Competition Enhancement Act×2

Affordable Prescriptions for Patients Act×2

Vaccine Policy×2

Coverage and Access and the Vaccine Injury Compensation Fund×2

DRUG Act×2

International Supply Chain×2

March-in rights×1

Issue mix

LDA general-issue codes weighted by activity count.

Medicare/Medicaid61

Health Issues58

Pharmacy17

Taxation/Internal Revenue Code8

Telecommunications6

Economics/Economic Development4

Financial Institutions/Investments/Securities4

Tariff (miscellaneous tariff bills)2

Trade (domestic/foreign)2